GIC-102, Intravenous Allogeneic NK Cells, in Subjects With Advanced Solid Cancers and R/R Hematologic Malignancies

NCT05880043 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors
Relapsed/Refractory Non-Hodgkin Lymphoma
Relapsed/Refractory Multiple Myeloma

Interventions

DRUG: GIC-102
DRUG: GIC-102

Sponsor

GI Cell, Inc.